WeDaita  |  AI Drug Discovery Platform
BioMedAI From Target to Candidate — in One Platform

An agentic AI platform for drug discovery. We automate complex research workflows by integrating and harnessing the power of AI across the drug discovery pipeline—so scientists can focus on what matters most and accelerate the path to new therapies.

90%
Reduction in early research time
70%
Faster drug design cycles (projected)
2×
Faster clinical trial execution (vision)
  Try BioMedAI   See It in Action   Book a Call

Solving Drug Discovery at Scale

Drug discovery has long been defined by decade-long timelines, billion-dollar costs, and high failure rates. WeDaita is changing that — with AI agents built to compress timelines, cut costs, and improve decision quality at every stage of the pipeline.

90%
Failure Rate
9 in 10 drug candidates fail — most due to poor target validation and inadequate early-stage evidence. WeDaita's DBRA agents surface higher-confidence targets from the start.
10–15
Years per Drug
A decade-plus of research, design, and trials before patients see results. WeDaita compresses the early discovery pipeline from years to weeks.
$2–3B
Per Drug Candidate
Billions spent per approved drug — driven by inefficiency and late-stage failures. WeDaita reduces the cost burden by cutting wasted research cycles early.
BioMedAI Platform

One Platform. Full Discovery Pipeline.

Three agent modules that cover the complete drug discovery workflow — from target to candidate.

Stage 1 — Early Research
DBRA
Deep Biomedical Research Agents
2 Agents Live
Solves the Haystack Problem — automating evidence synthesis to generate and validate novel drug targets — in hours, not months.
  • Deep Research on drug research
  • Disease-to-target hypothesis generation
  • Drug Target PrioritizationIn Dev
  • Drug RepurposingIn Dev
90%
Reduction in early research time
Stage 2 — Drug Design
ADDA
Autonomous Drug Design Agents
1 Agent Live
Bridges the Translation Gap — automating biologic and small molecule drug design to reduce preclinical failure rates.
  • Protein / antibody drug design
  • Peptide/MacrocycleIn Dev
  • Small molecule design & optimisationIn Dev
70%
Faster drug design cycles (projected)
Stage 3 — Clinical Trials
CTIA
Clinical Trial Intelligence Agents
Addresses Late-Stage Attrition — AI-assisted protocol design, predictive recruitment, and portfolio optimization.
  • Digital twin trial simulationRoadmap
  • Predictive patient recruitmentRoadmap
  • AI-assisted protocol designRoadmap
  • Portfolio optimizationRoadmap
2×
Faster clinical trial execution (vision)

Experience AI-Powered Drug Discovery

Watch our autonomous AI Scientists platform accelerate research from months to minutes

  • Real-time demonstration of AI agents in action
  • Target identification in minutes, not months
  • Comprehensive insights from 11 biomedical databases
  • Autonomous research with zero human intervention

Grounded in Primary Scientific Sources

Every insight traces back to 41 primary databases (PubMed, UniProt, ChEMBL, PDB, and more) and 173 scientific tools — not black-box outputs.

Built by Drug Discovery Scientists

Our team has decades of combined experience in computational biology, medicinal chemistry, and AI research.

Researcher in the Loop, Always

BioMedAI accelerates your thinking — your scientific judgement drives every key decision.

The Team Behind BioMedAI

Scientists, engineers, and domain experts united by one mission — making drug discovery faster and smarter.

Wenliang Zhang
Wenliang Zhang
Daitor
All Members  
Stay Ahead

AI Drug Discovery, Delivered Monthly

Get curated insights on AI-driven target identification, therapeutic design, and BioMedAI platform updates — directly to your inbox.

No spam. Unsubscribe at any time. We respect your privacy.

Ready to Accelerate Your Drug Discovery?

BioMedAI is live — start with target identification and protein drug design today, with more modules launching soon.

  Try BioMedAI   Book a Demo